Green; Simon Richard

Patent Applications and Registrations

Patent applications and USPTO patent grants for Green; Simon Richard.The latest application filed is for "new substituted cyanoindoline derivatives as nik inhibitors".

Company Profile

6.9.15

Green; Simon Richard - Harlow GB
Green; Simon Richard - Dundee GB
Green; Simon Richard - Cardiff GB
Green; Simon Richard - Holystone GB
Green; Simon Richard - Tyne & Wear GB
Green, Simon Richard - Newcastle upon Tyne GB

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cyanoindoline derivatives as NIK inhibitors Grant 11,186,589 - Stansfield , et al. November 30, 2	2021-11-30
Substituted cyanoindoline derivatives as NIK inhibitors Grant 11,180,487 - Stansfield , et al. November 23, 2	2021-11-23
Heteroaromatic derivatives as NIK inhibitors Grant 11,136,311 - Stansfield , et al. October 5, 2	2021-10-05
6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors Grant 11,001,569 - Stansfield , et al. May 11, 2	2021-05-11
New Substituted Cyanoindoline Derivatives As Nik Inhibitors App 20210087182 - STANSFIELD; Ian ; et al.	2021-03-25
Cyanoindoline Derivatives As Nik Inhibitors App 20210032267 - Stansfield; Ian ; et al.	2021-02-04
New 6-membered Heteroaromatic Substituted Cyanoindoline Derivatives As Nik Inhibitors App 20200109129 - STANSFIELD; Ian ; et al.	2020-04-09
Heteroaromatic Derivatives As Nik Inhibitors App 20190359598 - Stansfield; Ian ; et al.	2019-11-28
Cyanoindoline Derivatives As Nik Inhibitors App 20190119299 - Stansfield; Ian ; et al.	2019-04-25
Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine Grant 8,975,239 - Green , et al. March 10, 2	2015-03-10
Combinations Of Sapacitabine Or Cndac With Dna Methyltransferase Inhibitors Such As Decitabine And Procaine App 20140100187 - GREEN; Simon Richard ; et al.	2014-04-10
Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine Grant 8,530,445 - Green , et al. September 10, 2	2013-09-10
Combination Comprising Cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) And A Cytotoxic Agent App 20130196938 - GREEN; Simon Richard ; et al.	2013-08-01
Method For Selecting A Cancer Therapy App 20130005747 - GREEN; Simon Richard ; et al.	2013-01-03
Combinations Of Sapacitabine Or Cndac With Dna Methyltransferase Inhibitors Such As Decitabine And Procaine App 20110207692 - Green; Simon Richard ; et al.	2011-08-25
Combination of a CDK inhibitor and CS-682 or a metabolite thereof Grant 7,772,207 - Green , et al. August 10, 2	2010-08-10
Methods for the Treatment of Multiple Myeloma Using Roscovitine App 20070287718 - Green; Simon Richard ; et al.	2007-12-13
Combination of a Cdk Inhibitor and Cs-682 or a Metabolite Thereof App 20070270442 - Green; Simon Richard ; et al.	2007-11-22
Rinse-added fabric treatment composition, kit containing such, and method of use therefor App 20060075576 - Price; Kenneth Nathan ; et al.	2006-04-13
Rinse-added fabric treatment composition, kit containing such, and method of use therefor Grant 7,026,278 - Price , et al. April 11, 2	2006-04-11
Combination of a cdk inhibitor and 5-fu for the tratment of cancer App 20050164976 - Green, Simon Richard ; et al.	2005-07-28
Methods of treatment of chronic lymphocytic leukemia using roscovitine App 20050153991 - Gianella-Borradori, Athos ; et al.	2005-07-14
Rinse-added fabric treatment composition, kit containing such, and method of use therefor App 20020111285 - Price, Kenneth Nathan ; et al.	2002-08-15

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.